## Jeffrey A Gelfand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4367729/publications.pdf

Version: 2024-02-01

100 papers 8,032 citations

76326 40 h-index 88 g-index

102 all docs

 $\begin{array}{c} 102 \\ \\ \text{docs citations} \end{array}$ 

times ranked

102

5789 citing authors

#	Article	IF	Citations
1	Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer Journal of Clinical Oncology, 2021, 39, 6075-6075.	1.6	1
2	Clofazimine for babesiosis: preclinical data support a clinical trial. Journal of Infectious Diseases, 2021, , .	4.0	1
3	Case Report: Overwhelming Babesia Parasitemia Successfully Treated Promptly With RBC Apheresis and Triple Therapy With Clindamycin, Azithromycin, and Atovaquone. Open Forum Infectious Diseases, 2020, 7, ofaa448.	0.9	4
4	Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nature Biotechnology, 2020, 38, 1174-1183.	17.5	251
5	Clinical sensitivity and interpretation of PCR and serological COVIDâ€19 diagnostics for patients presenting to the hospital. FASEB Journal, 2020, 34, 13877-13884.	0.5	117
6	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. Journal of Infectious Diseases, 2020, 222, 1955-1959.	4.0	72
7	Photoinactivation of <i>Moraxella catarrhalis</i> Using 405â€nm Blue Light: Implications for the Treatment of Otitis Media. Photochemistry and Photobiology, 2020, 96, 611-617.	2.5	12
8	Rethinking the role of hydroxychloroquine in the treatment of COVIDâ€19. FASEB Journal, 2020, 34, 6027-6037.	0.5	110
9	Photoinactivation of Neisseria gonorrhoeae: A Paradigm-Changing Approach for Combating Antibiotic-Resistant Gonococcal Infection. Journal of Infectious Diseases, 2019, 220, 873-881.	4.0	25
10	Dual blockade of CXCL12â€CXCR4 and PDâ€1–PDâ€11 pathways prolongs survival of ovarian tumor–bearin mice by prevention of immunosuppression in the tumor microenvironment. FASEB Journal, 2019, 33, 6596-6608.	g 0.5	120
11	A pilot clinical trial of a nearâ€infrared laser vaccine adjuvant: safety, tolerability, and cutaneous immune cell trafficking. FASEB Journal, 2019, 33, 3074-3081.	0.5	12
12	AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression. Cancer Immunology Research, 2018, 6, 539-551.	3.4	29
13	Brief Exposure of Skin to Near-Infrared Laser Modulates Mast Cell Function and Augments the Immune Response. Journal of Immunology, 2018, 201, 3587-3603.	0.8	18
14	Antimicrobial Photodynamic Inactivation Mediated by Tetracyclines in Vitro and in Vivo: Photochemical Mechanisms and Potentiation by Potassium Iodide. Scientific Reports, 2018, 8, 17130.	3.3	25
15	Tetracyclines function as dual-action light-activated antibiotics. PLoS ONE, 2018, 13, e0196485.	2.5	22
16	Antimicrobial photodynamic therapy mediated by methylene blue and potassium iodide to treat urinary tract infection in a female rat model. Scientific Reports, 2018, 8, 7257.	3.3	55
17	Neurogenic Bladder: Recurrent Urinary Tract Infections—Beyond Antibiotics. Current Bladder Dysfunction Reports, 2018, 13, 191-200.	0.5	6
18	Semiconductor diode laser device adjuvanting intradermal vaccine. Vaccine, 2017, 35, 2404-2412.	3.8	16

#	Article	IF	Citations
19	MP23-18 SYNERGISTIC PHOTODYNAMIC THERAPY FOR CATHETER-ASSOCIATED URINARY TRACT INFECTION IN RATS. Journal of Urology, 2017, 197, .	0.4	1
20	Near-Infrared 1064 nm Laser Modulates Migratory Dendritic Cells To Augment the Immune Response to Intradermal Influenza Vaccine. Journal of Immunology, 2017, 199, 1319-1332.	0.8	24
21	Abstract 3649: Combination of mesothelin-targeted immune-activating fusion protein and anti-PD-L1 augments antitumor immunity and prolongs survival in murine model of ovarian cancer., 2017,,.		0
22	Abstract 1633: Immunotherapy for malignant mesothelioma that combines a mesothelia-targeted immune-activating protein and CXCL12/CXCR4 blockade. , 2017, , .		0
23	Immune Profiling of Coxiella burnetii Infection by Mass Cytometry. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
24	GM-CSF Enhances Macrophage Glycolytic Activity In Vitro and Improves Detection of Inflammation In Vivo. Journal of Nuclear Medicine, 2016, 57, 1428-1435.	5.0	15
25	Risks Associated With Lentiviral Vector Exposures and Prevention Strategies. Journal of Occupational and Environmental Medicine, 2016, 58, 1159-1166.	1.7	94
26	Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?. Expert Review of Vaccines, 2015, 14, 435-446.	4.4	7
27	Babesia Species. , 2015, , 3165-3172.e2.		3
28	VaxCelerate II: Rapid development of a self-assembling vaccine for Lassa fever. Human Vaccines and Immunotherapeutics, 2014, 10, 3022-3038.	3.3	23
29	Laser vaccine adjuvants. Human Vaccines and Immunotherapeutics, 2014, 10, 1892-1907.	3.3	38
30	A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. Journal of Hematology and Oncology, 2014, 7, 15.	17.0	34
31	Increased dense erythrocytes in flame-burned patients. Clinical Hemorheology and Microcirculation, 2013, 53, 349-356.	1.7	0
32	Near-Infrared Laser Adjuvant for Influenza Vaccine. PLoS ONE, 2013, 8, e82899.	2.5	39
33	Accelerated vaccine development against emerging infectious diseases. Human Vaccines and Immunotherapeutics, 2012, 8, 1010-1012.	3.3	2
34	Abstract 1578: MTBhsp70 fusion protein targeting mesothelin augments tumor specific T cell responses and prolongs survival in a murine model of ovarian cancer. , 2012, , .		0
35	A Novel Laser Vaccine Adjuvant Increases the Motility of Antigen Presenting Cells. PLoS ONE, 2010, 5, e13776.	2.5	65
36	Babesia Species. , 2010, , 3539-3545.		1

#	Article	IF	CITATIONS
37	Health Effects of Salicylates in Foods and Drugs. Nutrition Reviews, 2009, 54, 225-240.	5.8	17
38	Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases, 2008, 46, 370-376.	5.8	299
39	Case 17-2007. New England Journal of Medicine, 2007, 356, 2313-2319.	27.0	39
40	Babesia microti Primarily Invades Mature Erythrocytes in Mice. Infection and Immunity, 2006, 74, 3204-3212.	2.2	26
41	A novel automated screening and interpretation process for cervical cytology using the internet transmission of low-resolution images. Cancer, 2005, 105, 199-206.	4.1	25
42	Species-Specific Bacteria Identification Using Differential Mobility Spectrometry and Bioinformatics Pattern Recognition. Analytical Chemistry, 2005, 77, 5930-5937.	6.5	79
43	Ageâ€Associated Decline in Resistance toBabesia microtils Genetically Determined. Journal of Infectious Diseases, 2004, 189, 1721-1728.	4.0	59
44	Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells. Surgery, 2004, 135, 544-554.	1.9	19
45	Babesiosis: An update on epidemiology and treatment. Current Infectious Disease Reports, 2003, 5, 53-58.	3.0	14
46	Both C3a and C3a <sub>desAr</sub> g Regulate Interleukinâ€6 Synthesis in Human Peripheral Blood Mononuclear Cells. Journal of Infectious Diseases, 1998, 177, 1622-1628.	4.0	62
47	Interaction with Autologous Platelets Multiplies Interleukin-l and Tumor Necrosis Factor Production in Mononuclear Cells. Journal of Infectious Diseases, 1997, 175, 123-129.	4.0	37
48	Interstitial Cystitis and Bladder Mastocytosis in a Woman with Chronic Urticaria. Scandinavian Journal of Urology and Nephrology, 1997, 31, 497-500.	1.4	9
49	Alkylation of cellulosic membranes results in reduced complement activation. Journal of Biomaterials Science, Polymer Edition, 1996, 7, 707-714.	3.5	7
50	CYTOKINES AND ANTICYTOKINE THERAPY IN THE TREATMENT OF SHOCK. Shock, 1995, 4, 11.	2.1	0
51	Methotrexate Treatment of Idiopathic Granulomatous Hepatitis. Annals of Internal Medicine, 1995, 122, 592.	3.9	44
52	Coagulation of Whole Blood Stimulates Interleukin-1Â Gene Expression. Journal of Infectious Diseases, 1995, 172, 308-311.	4.0	36
53	Effects of malignancy and interleukin-2 infusion on gut macromolecular permeability. Critical Care Medicine, 1995, 23, 1801-1806.	0.9	3
54	Too little oxygen, too little interleukin-2. Critical Care Medicine, 1994, 22, 187.	0.9	5

#	Article	IF	CITATIONS
55	Acute respiratory failure in patients treated for babesiosis American Journal of Respiratory and Critical Care Medicine, 1994, 149, 1689-1691.	5.6	34
56	Platelet activating factor-antagonist improves survival in experimental staphylococcal septicemia. Journal of Pediatric Surgery, 1994, 29, 1055-1058.	1.6	7
57	Intestinal Production of Interleukin- $\hat{\text{Il}}$ during Endotoxemia in the Mouse. Journal of Surgical Research, 1993, 54, 584-591.	1.6	60
58	Interleukin-1 Pretreatment Protects against Endotoxin-Induced Hypotension in Rabbits: Association with Decreased Tumor Necrosis Factor Levels. Journal of Infectious Diseases, 1993, 167, 244-247.	4.0	9
59	Relative Production of ILâ€1β and TNFα by Mononuclear Cells After Exposure to Dental Implants. Journal of Periodontology, 1992, 63, 426-430.	3.4	35
60	Diminished In Vitro Production of Interleukin-1 and Tumor Necrosis Factor-α during Acute Visceral Leishmaniasis and Recovery after Therapy. Journal of Infectious Diseases, 1992, 165, 1094-1102.	4.0	36
61	Circulating interleukin- $1\hat{l}^2$ and tumor necrosis factor- $\hat{l}$ ± concentrations after burn injury in humans. Critical Care Medicine, 1992, 20, 1414-1419.	0.9	142
62	A specific receptor antagonist for interleukin 1 prevents <i>Escherichia coli</i> â€induced shock in rabbits. FASEB Journal, 1991, 5, 338-343.	0.5	443
63	Charles A. Dinarello, MD. Critical Care Medicine, 1991, 19, 602.	0.9	1
64	Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli Journal of Clinical Investigation, 1991, 87, 1925-1935.	8.2	252
65	Experimental Hemorrhage and Blunt Trauma Do Not Increase Circulating Tumor Necrosis Factor. Journal of Trauma, 1991, 31, 1063-1067.	2.3	0
66	Cytokines, Acute Phase Proteins, and Tissue Injury. Annals of the New York Academy of Sciences, 1990, 587, 351-361.	3.8	26
67	Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever. Journal of Infectious Diseases, 1990, 161, 79-84.	4.0	755
68	Interleukin-1 and the response to injury. Immunologic Research, 1989, 8, 118-129.	2.9	43
69	Endotoxin Suppresses Surfactant Synthesis in Cultured Rat Lung Cells. Journal of Trauma, 1989, 29, 180-188.	2.3	5
70	Impact of C-reactive Protein (CRP) on Surfactant Function. Journal of Trauma, 1989, 29, 1690-1697.	2.3	36
71	PLASMAPHERESIS FOR FULMINANT MENINGOCOCCEMIA. Pediatric Infectious Disease Journal, 1989, 8, 399.	2.0	49
72	C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha Journal of Experimental Medicine, 1988, 168, 443-448.	8.5	213

#	Article	IF	CITATIONS
73	Concentrations of Immunoreactive Human Tumor Necrosis Factor Alpha Produced by Human Mononuclear Cells In Vitro. Journal of Leukocyte Biology, 1988, 43, 216-223.	3.3	161
74	Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition Journal of Clinical Investigation, 1988, 81, 1162-1172.	8.2	943
75	Experimental Bacteroides fragilis Bacteremia in a Primate Model. Journal of Trauma, 1985, 25, 1156-1162.	2.3	21
76	Complement activation by synthetic vascular prostheses. Journal of Vascular Surgery, 1984, 1, 829-838.	1.1	88
77	Infections in burn patients: A paradigm for cutaneous infection in the patient at risk. American Journal of Medicine, 1984, 76, 158-165.	1.5	18
78	Complement activation by synthetic vascular prostheses. Journal of Vascular Surgery, 1984, 1, 829-838.	1.1	63
79	Exploiting Sex for Therapeutic Purposes. New England Journal of Medicine, 1983, 308, 1417-1419.	27.0	32
80	Preferential Activation and Depletion of the Alternative Complement Pathway by Burn Injury. Annals of Surgery, 1983, 198, 58-62.	4.2	65
81	A Study of Optimal Reaction Conditions for an Assay of the Human Alternative Complement Pathway. American Journal of Clinical Pathology, 1983, 79, 65-72.	0.7	68
82	Alternative complement pathway activation increases mortality in a model of burn injury in mice Journal of Clinical Investigation, 1982, 70, 1170-1176.	8.2	65
83	Activation of the Alternative Complement Pathway by Blood Culture Isolates of <i>Bacteroides fragilis</i> Infection and Immunity, 1981, 34, 303-305.	2.2	7
84	Host Factors in the Formation of Abscesses. Journal of Infectious Diseases, 1980, 142, 40-49.	4.0	35
85	Replacement Therapy in Hereditary Angioedema. New England Journal of Medicine, 1980, 302, 542-546.	27.0	225
86	Danazol-induced Augmentation of Serum $\hat{l}\pm 1$ -Antitrypsin Levels in Individuals with Marked Deficiency of this Antiprotease. Journal of Clinical Investigation, 1980, 66, 82-87.	8.2	92
87	A sensitive microassay for the murine alternative compliment pathway. Journal of Immunological Methods, 1979, 31, 283-290.	1.4	14
88	Acquired C1 Esterase Inhibitor Deficiency and Angioedema. Medicine (United States), 1979, 58, 321-328.	1.0	182
89	Response of Variant Hereditary Angioedema Phenotypes to Danazol Therapy. Journal of Clinical Investigation, 1979, 64, 280-286.	8.2	69
90	Role of Complement in Host Defense against Experimental Disseminated Candidiasis. Journal of Infectious Diseases, 1978, 138, 9-16.	4.0	92

#	Article	IF	CITATIONS
91	SYSTEMIC CAPILLARY LEAK SYNDROME AND MONOCLONAL IgG GAMMOPATHY. Medicine (United States), 1977, 56, 225-240.	1.0	134
92	Immunoglobulin and Complement Receptors on Human Eosinophils and Their Role in Cellular Adherence to Schistosomules. American Journal of Tropical Medicine and Hygiene, 1977, 26, 134-141.	1.4	49
93	Treatment of Hereditary Angioedema with Danazol. New England Journal of Medicine, 1976, 295, 1444-1448.	27.0	610
94	Hereditary Angioedema: the Clinical Syndrome and Its Management. Annals of Internal Medicine, 1976, 84, 580.	3.9	558
95	Endotoxemia Associated with the Jarisch-Herxheimer Reaction. New England Journal of Medicine, 1976, 295, 211-213.	27.0	77
96	Pulmonary Aspergillosis, Inhalation of Contaminated Marijuana Smoke, Chronic Granulomatous Disease. Annals of Internal Medicine, 1975, 82, 682.	3.9	78
97	Hereditary angioedema: The use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. Journal of Allergy and Clinical Immunology, 1975, 55, 386-393.	2.9	113
98	Active Histoplasma meningitis of 22 years' duration. JAMA - Journal of the American Medical Association, 1975, 233, 1294-1295.	7.4	1
99	Renal Failure in Paroxysmal Hemoglobinuria. JAMA - Journal of the American Medical Association, 1974, 227, 440.	7.4	2
100	Babesiosis., 0,, 99-112.		0